RPE

Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD

Retrieved on: 
Wednesday, March 15, 2023
Vance DeGeneres, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Risk, Visual acuity, Ophthalmology, Retinal pigment epithelium, RPE, FDA, AMD, Safety, Geographic atrophy, Food, IND, Pharmaceutical industry, Cognition

NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that its Investigational New Drug (IND) application for the investigation of CT1812 for geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) has been cleared by the U.S. Food and Drug Administration (FDA).

Key Points: 
  • NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that its Investigational New Drug (IND) application for the investigation of CT1812 for geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) has been cleared by the U.S. Food and Drug Administration (FDA).
  • Cognition plans to initiate the Phase 2 MAGNIFY trial of its oral drug candidate, CT1812 in 2023 in individuals with dry AMD who have measurable GA.
    “We enjoyed a collaborative dialogue with the ophthalmology division of the FDA during our pre-IND meeting and are excited to assess the potential of CT1812 to impact GA and slow the decline in visual acuity in people with dry AMD,” said Anthony Caggiano, M.D., Ph.D. , Cognition’s chief medical officer and head of R&D.
  • “Expansion of our pipeline programs into GA is an excellent example of how we are leveraging our scientific expertise to tackle some of the most challenging diseases,” added Lisa Ricciardi , president and CEO of Cognition.
  • “Looking ahead, I’m excited by our continued clinical progress as we advance CT1812 through ongoing studies and now into this new indication.”

NOVA Chemicals Launches New Circular Solutions Business to Meet Growing Demand for Recycled Plastics

Retrieved on: 
Wednesday, February 15, 2023
Nova Chemicals, Recycling, RPE, HDPE, Nova, Safety, NOVA, Health, Polyethylene, AB, Marketing, Plastic, Environment, Bottled water, Lumber, Thermoplastic

CALGARY, AB, Feb. 15, 2023 (GLOBE NEWSWIRE) -- NOVA Chemicals Corporation (“NOVA Chemicals”) today announced the establishment of NOVA Circular Solutions, a new line of business focusing on lower-emission, recycled solutions that will help reshape a better, more sustainable world.

Key Points: 
  • CALGARY, AB, Feb. 15, 2023 (GLOBE NEWSWIRE) -- NOVA Chemicals Corporation (“NOVA Chemicals”) today announced the establishment of NOVA Circular Solutions, a new line of business focusing on lower-emission, recycled solutions that will help reshape a better, more sustainable world.
  • NOVA Circular Solutions will be home to the SYNDIGOTM brand, the company’s newest portfolio of recycled polyethylene (rPE).
  • NOVA Circular Solutions is led by a team of experts in plastics development, recycling technology, additive science, packaging design, and regulatory compliance.
  • There is a growing demand for recycled products and the SYNDIGO resins are poised to meet those needs in North America.

Soldier Systems Market worth $12.8 Billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, February 10, 2023
Rheinmetall, Application software, Defense, North American power transmission grid, Original equipment manufacturer, C4ISR, Mounted Soldier System, Commercial, Law enforcement, Hardware, Acquisition, Navy, General Dynamics, Thales Group, Elbit Systems, BAE Systems, USB On-The-Go, Air force, USD, Component, Growth, Indian MRO Industry, Army, National Military Command Center, Communication, Vehicle, Saab AB, RPE, Intelligence, surveillance, target acquisition, and reconnaissance, Drug, Satellite navigation device, Arms industry, Upgrade, Application, Installation, Homeland security, Airborne

Factors such as the emphasis on improving troops situational awareness on the battlefield and the increased incidences of asymmetric warfare are positively driving the growth of the soldier systems market.

Key Points: 
  • Factors such as the emphasis on improving troops situational awareness on the battlefield and the increased incidences of asymmetric warfare are positively driving the growth of the soldier systems market.
  • Furthermore, rising defense spending, particularly in emerging economies, and consequent expenditures in purchasing such systems drive market growth.
  • The demand for soldier systems has increased significantly worldwide due to technological advancements in soldier system devices.
  • The Soldier System market industry has been studied in North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

Soldier Systems Market worth $12.8 Billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, February 10, 2023
Rheinmetall, Application software, Defense, North American power transmission grid, Original equipment manufacturer, C4ISR, Mounted Soldier System, Commercial, Law enforcement, Hardware, Acquisition, Navy, General Dynamics, Thales Group, Elbit Systems, BAE Systems, USB On-The-Go, Air force, USD, Component, Growth, Indian MRO Industry, Army, National Military Command Center, Communication, Vehicle, Saab AB, RPE, Intelligence, surveillance, target acquisition, and reconnaissance, Drug, Satellite navigation device, Arms industry, Upgrade, Application, Installation, Homeland security, Airborne

Factors such as the emphasis on improving troops situational awareness on the battlefield and the increased incidences of asymmetric warfare are positively driving the growth of the soldier systems market.

Key Points: 
  • Factors such as the emphasis on improving troops situational awareness on the battlefield and the increased incidences of asymmetric warfare are positively driving the growth of the soldier systems market.
  • Furthermore, rising defense spending, particularly in emerging economies, and consequent expenditures in purchasing such systems drive market growth.
  • The demand for soldier systems has increased significantly worldwide due to technological advancements in soldier system devices.
  • The Soldier System market industry has been studied in North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

HUIDAGENE THERAPEUTICS ANNOUNCES IND ACTIVE FOR THE MULTINATIONAL TRIAL OF HG004 TO TREAT INHERITED BLINDNESS

Retrieved on: 
Saturday, January 28, 2023
Retinal pigment epithelium, IND, DSM-IV codes, Visual impairment, IIT, CRISPR, Human, Retina, Entrepreneurship, Partnership, Paratriathlon, FDA, CMC, Patient, Risk, Food, AAV2, AAV, Food and Drug Administration, RPE, Week, Pharmaceutical industry, Vaccine, RPE65, US FDA

SHANGHAI and CLINTON, N.J., Jan. 27, 2023 /PRNewswire/ -- HuidaGene Therapeutics (HuidaGene), a clinical-stage biotechnology company developing CRISPR-based programmable genomic medicine, announces that the US.

Key Points: 
  • SHANGHAI and CLINTON, N.J., Jan. 27, 2023 /PRNewswire/ -- HuidaGene Therapeutics (HuidaGene), a clinical-stage biotechnology company developing CRISPR-based programmable genomic medicine, announces that the US.
  • "We are thrilled to have received the IND clearance of our HG004 program from US FDA, marking our first IND clearance as a company and our first retinal disorder program to reach clinical development stage," said Xuan Yao, Ph.D., Co-founder and Chief Executive Officer of HuidaGene.
  • The goal of the HG004 program is to develop a one-time, non-AAV2 gene replacement therapy to restore, treat, and prevent blindness of children and adults with severe visual impairment or blindness due to RPE65 mutation-associated retinopathies globally."
  • Investigational HG004 is a novel ophthalmic injection that is being developed to treat RPE65 retinopathies.

HUIDAGENE THERAPEUTICS ANNOUNCES IND ACTIVE FOR THE MULTINATIONAL TRIAL OF HG004 TO TREAT INHERITED BLINDNESS

Retrieved on: 
Saturday, January 28, 2023
Retinal pigment epithelium, IND, DSM-IV codes, Visual impairment, IIT, CRISPR, Human, Retina, Entrepreneurship, Partnership, Paratriathlon, FDA, CMC, Patient, Risk, Food, AAV2, AAV, Food and Drug Administration, RPE, Week, Pharmaceutical industry, Vaccine, RPE65, US FDA

SHANGHAI and CLINTON, N.J., Jan. 28, 2023 /PRNewswire/ -- HuidaGene Therapeutics (HuidaGene), a clinical-stage biotechnology company developing CRISPR-based programmable genomic medicine, announces that the US.

Key Points: 
  • SHANGHAI and CLINTON, N.J., Jan. 28, 2023 /PRNewswire/ -- HuidaGene Therapeutics (HuidaGene), a clinical-stage biotechnology company developing CRISPR-based programmable genomic medicine, announces that the US.
  • "We are thrilled to have received the IND clearance of our HG004 program from US FDA, marking our first IND clearance as a company and our first retinal disorder program to reach clinical development stage," said Xuan Yao, Ph.D., Co-founder and Chief Executive Officer of HuidaGene.
  • The goal of the HG004 program is to develop a one-time, non-AAV2 gene replacement therapy to restore, treat, and prevent blindness of children and adults with severe visual impairment or blindness due to RPE65 mutation-associated retinopathies globally."
  • Investigational HG004 is a novel ophthalmic injection that is being developed to treat RPE65 retinopathies.

Stargardt Disease Drug Pipeline Research Report 2022: Insights on 18+ Xompanies and 20+ Pipeline Drugs - Therapeutic Assessments by Product Type, Stage, Route of Administration, and Molecule Type - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 14, 2022
Health, Biotechnology, Therapy, NDA, Route, RPE, Triglyceride, Lipoprotein, Administration, News, Clinical trial, Route of administration, Eye, Tissue, STRA6, Discovery, RBP4, Vitamin A, Acquisition, Medical device, Pharmaceutical industry, Stargardt disease

This "Stargardt disease Pipeline Insight, 2022" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Stargardt disease pipeline landscape.

Key Points: 
  • This "Stargardt disease Pipeline Insight, 2022" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Stargardt disease pipeline landscape.
  • It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
  • The assessment part of the report embraces, in depth Stargardt disease commercial assessment and clinical assessment of the pipeline products under development.
  • Stargardt disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD

Retrieved on: 
Thursday, December 1, 2022
Molecule, COVID-19, Neurodegeneration, RPE, Dementia, Severe cognitive impairment, Administration, Geographic atrophy, Laboratory, Potency (pharmacology), Food, DLB, Cell, Retinal, Risk, Therapy, Degenerative disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Drusen, Macular degeneration, Retina, IPSC, Protein, Inflammation, Central nervous system, Disease, Cognition, AMD, POS, Alzheimer's disease, Lewy body, GA, Intellectual property, Phase II, Vance DeGeneres, Traffic barrier, Securities & Exchange Commission of Pakistan, Oxidative stress, Eye, Biology, Neuron, Dry, FDA, Pharmaceutical industry, Vaccine

Complement inhibition has shown potential in clinical trials but must be given via intravitreal injection to each affected eye.

Key Points: 
  • Complement inhibition has shown potential in clinical trials but must be given via intravitreal injection to each affected eye.
  • CT1812 is an experimental oral sigma-2 (-2) receptor modulator currently in Phase 2 clinical trials for both Alzheimer's disease and dementia with Lewy bodies (DLB).
  • The proteomic analyses from our clinical studies in neurodegenerative disease were instrumental in identifying dry AMD as an indication of interest, explained Mary Hamby, Ph.D. , VP of biology at Cognition Therapeutics.
  • We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimers disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD).

Apex Physics Partners (APP) Expands Its National Footprint with New Partnerships in Arizona and Florida

Retrieved on: 
Wednesday, November 16, 2022
Hospitals, General Health, Health, Other Health, Marketing, Physics, Insurance, Information technology, Fear, Fusion, RPE, APP, Growth, Health, Google Images, Patient, Medical device, Medical imaging

Apex Physics Partners (APP), the largest outsourced medical physics services company in North America, today announced that two new companies, Fusion Physics, LLC in Tampa, Florida, and Radiation Physics & Engineering, Inc (RPE) in Phoenix, Arizona, are now part of its network.

Key Points: 
  • Apex Physics Partners (APP), the largest outsourced medical physics services company in North America, today announced that two new companies, Fusion Physics, LLC in Tampa, Florida, and Radiation Physics & Engineering, Inc (RPE) in Phoenix, Arizona, are now part of its network.
  • Headquartered in Phoenix, RPE offers diagnostic medical physics services to healthcare and environmental companies across Arizona, New Mexico and the Southwest.
  • Our purpose is to enable healthier communities, and our latest partnerships demonstrate our ongoing commitment to this goal, said Michael Curry, CEO of Apex Physics Partners.
  • Apex Physics Partners ( http://www.apexphysicspartners.com ) is the largest outsourced medical physics services organization in North America, offering diagnostic and therapy medical physics services to large hospital systems, healthcare facilities, imaging centers and cancer care groups throughout the U.S.

NOVA Chemicals Launches 100% Post-Consumer Mechanically Recycled Polyethylene Resin

Retrieved on: 
Tuesday, October 25, 2022
Commercial, Nova Chemicals, Mubadala Investment Company, LinkedIn, Emirate, Safety, AB, Growth, Goal, Center, NOVA, Responsible Care, Climate change, PE, Leadership, Happiness, GLOBE, Recycling, Health, Association, Carbon, RPE, Performance Application Programming Interface, Nova, Thermoplastic

CALGARY, AB, Oct. 25, 2022 (GLOBE NEWSWIRE) -- NOVA Chemicals Corporation (NOVA Chemicals), a leading producer of polyethylene resins, announced the launch of its new, mechanically recycled polyethylene resin: EX-PCR-NC4.

Key Points: 
  • CALGARY, AB, Oct. 25, 2022 (GLOBE NEWSWIRE) -- NOVA Chemicals Corporation (NOVA Chemicals), a leading producer of polyethylene resins, announced the launch of its new, mechanically recycled polyethylene resin: EX-PCR-NC4.
  • NOVA Chemicals rPE is sourced from distribution center flexible film, which includes a blend of back-of-store stretch and front-of-store consumer drop off.
  • NOVA Chemicals continues to demonstrate leadership in providing sustainable polyethylene solutions, and we look forward to additional growth in this space.
  • The NOVA Chemicals logo is a registered trademark of NOVA Brands Ltd.; authorized use.